|
1
|
Miao H, Hartman M, Bhoo-Pathy N, Lee SC,
Taib NA, Tan EY, Chan P, Moons KG, Wong HS, Goh J, et al:
Predicting survival of de novo metastatic breast cancer in Asian
women: Systematic review and validation study. PLoS One.
9:e937552014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cummings MC, Chambers R, Simpson PT and
Lakhani SR: Molecular classification of breast cancer: Is it time
to pack up our microscopes? Pathology. 43:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ginsburg GS and Willard HF: Genomic and
personalized medicine: Foundations and applications. Transl Res.
154:277–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dechaphunkul A, Phukaoloun M,
Kanjanapradit K, Graham K, Ghosh S, Santos C and Mackey JR:
Prognostic significance of tissue inhibitor of metalloproteinase-1
in breast cancer. Int J Breast Cancer. 2012:2908542012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Geyer FC, Rodrigues DN, Weigelt B and
Reis-Filho JS: Molecular classification of estrogen
receptor-positive/luminal breast cancers. Adv Anat Pathol.
19:39–53. 2012. View Article : Google Scholar
|
|
6
|
Duffy MJ: Proteases as prognostic markers
in cancer. Clin Cancer Res. 2:613–618. 1996.PubMed/NCBI
|
|
7
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flores-Reséndiz D, Castellanos-Juárez E
and Benítez-Bribiesca L: Proteases in cancer progression. Gac Med
Mex. 145:131–142. 2009.In Spanish.
|
|
9
|
Netzel-Arnett S, Hooper JD, Szabo R,
Madison EL, Quigley JP, Bugge TH and Antalis TM: Membrane anchored
serine proteases: A rapidly expanding group of cell surface
proteolytic enzymes with potential roles in cancer. Cancer
Metastasis Rev. 22:237–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hooper JD, Clements JA, Quigley JP and
Antalis TM: Type II transmembrane serine proteases. Insights into
an emerging class of cell surface proteolytic enzymes. J Biol Chem.
276:857–860. 2001. View Article : Google Scholar
|
|
11
|
Choi SY, Bertram S, Glowacka I, Park YW
and Pöhlmann S: Type II transmembrane serine proteases in cancer
and viral infections. Trends Mol Med. 15:303–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Aberasturi AL and Calvo A: TMPRSS4: An
emerging potential therapeutic target in cancer. Br J Cancer.
112:4–8. 2015. View Article : Google Scholar :
|
|
13
|
Jung H, Lee KP, Park SJ, Park JH, Jang YS,
Choi SY, Jung JG, Jo K, Park DY, Yoon JH, et al: TMPRSS4 promotes
invasion, migration and metastasis of human tumor cells by
facilitating an epithelial-mesenchymal transition. Oncogene.
27:2635–2647. 2008. View Article : Google Scholar
|
|
14
|
Kim S, Kang HY, Nam EH, Choi MS, Zhao XF,
Hong CS, Lee JW, Lee JH and Park YK: TMPRSS4 induces invasion and
epithelial-mesenchymal transition through upregulation of integrin
alpha5 and its signaling pathways. Carcinogenesis. 31:597–606.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang CH, Guo ZY, Chen ZT, Zhi XT, Li DK,
Dong ZR, Chen ZQ, Hu SY and Li T: TMPRSS4 facilitates
epithelial-mesenchymal transition of hepatocellular carcinoma and
is a predictive marker for poor prognosis of patients after
curative resection. Sci Rep. 5:123662015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: : AJCC Cancer Staging Manual. 7th edition.
Springer; New York, NY: pp. 237–246. 2010
|
|
17
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO classification of tumours of the breast.
World Health Organization classification of tumours. 4th edition.
IARC Press; Lyon: 2012
|
|
18
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al American Society of Clinical Oncology; College
of American Pathologists: Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American Society
of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szabo R and Bugge TH: Type II
transmembrane serine proteases in development and disease. Int J
Biochem Cell Biol. 40:1297–1316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Antalis TM, Bugge TH and Wu Q:
Membrane-anchored serine proteases in health and disease. Prog Mol
Biol Transl Sci. 99:1–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wallrapp C, Hähnel S, Müller-Pillasch F,
Burghardt B, Iwamura T, Ruthenbürger M, Lerch MM, Adler G and Gress
TM: A novel transmembrane serine protease (TMPRSS3) overexpressed
in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
|
|
22
|
Kebebew E, Peng M, Reiff E, Duh QY, Clark
OH and McMillan A: ECM1 and TMPRSS4 are diagnostic markers of
malignant thyroid neoplasms and improve the accuracy of fine needle
aspiration biopsy. Ann Surg. 242:353–363. 2005.PubMed/NCBI
|
|
23
|
Nguyen TH, Weber W, Havari E, Connors T,
Bagley RG, McLaren R, Nambiar PR, Madden SL, Teicher BA, Roberts B,
et al: Expression of TMPRSS4 in non-small cell lung cancer and its
modulation by hypoxia. Int J Oncol. 41:829–838. 2012.PubMed/NCBI
|
|
24
|
Larzabal L, Nguewa PA, Pio R, Blanco D,
Sanchez B, Rodríguez MJ, Pajares MJ, Catena R, Montuenga LM and
Calvo A: Overexpression of TMPRSS4 in non-small cell lung cancer is
associated with poor prognosis in patients with squamous histology.
Br J Cancer. 105:1608–1614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang A, Zhou H, Zhao H, Quan Y, Feng B
and Zheng M: TMPRSS4 correlates with colorectal cancer pathological
stage and regulates cell proliferation and self-renewal ability.
Cancer Biol Ther. 15:297–304. 2014. View Article : Google Scholar :
|
|
26
|
Liang B, Wu M, Bu Y, Zhao A and Xie F:
Prognostic value of TMPRSS4 expression in patients with breast
cancer. Med Oncol. 30:4972013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng D, Kong H and Li Y: TMPRSS4 as a
poor prognostic factor for triple-negative breast cancer. Int J Mol
Sci. 14:14659–14668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamamoto J, Soejima K, Naoki K, Yasuda H,
Hayashi Y, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, et al:
Methylation-induced downregulation of TFPI-2 causes TMPRSS4
overexpression and contributes to oncogenesis in a subset of
non-small-cell lung carcinoma. Cancer Sci. 106:34–42. 2015.
View Article : Google Scholar :
|
|
29
|
Brockhausen J, Tay SS, Grzelak CA,
Bertolino P, Bowen DG, d'Avigdor WM, Teoh N, Pok S, Shackel N,
Gamble JR, et al: miR-181a mediates TGF-β-induced hepatocyte EMT
and is dysregulated in cirrhosis and hepatocellular cancer. Liver
Int. 35:240–253. 2015. View Article : Google Scholar
|
|
30
|
Xu J, Li X, Yang H, Chang R, Kong C and
Yang L: SIN1 promotes invasion and metastasis of hepatocellular
carcinoma by facilitating epithelial-mesenchymal transition.
Cancer. 119:2247–2257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi SY, Shin HC, Kim SY and Park YW: Role
of TMPRSS4 during cancer progression. Drug News Perspect.
21:417–423. 2008.PubMed/NCBI
|
